Takeda offers Vyvanse rebate

Nicholas O’Donoghue 18/12/2025

Vyvanse sponsor “committed to ensuring pharmacies are not out of pocket”, after $50 PBS price cut Pharmacies have until 31 December to submit claims for a $55 per unit rebate for Vyvanse (lisdexamfetamine dimesilate) stock held as of 30 November 2025. The move comes after reports that pharmacies were left thousands of dollars out of pocket

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Takeda offers Vyvanse rebate

Previous Creon shortage continues

Next A baker’s dozen of panel hearings

MENU

ajp.com.au

Previous Creon shortage continues

Next A baker’s dozen of panel hearings

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.